Capping-reducing agent

Procedure. Samples are collected in 40-mL vials with screw-caps lined with a Teflon septum. Fill the vial to overflowing, ensuring that there are no air bubbles. Add a reducing agent of ascorbic acid (25 mg/40 mL) to quench the further production of trihalomethanes, and seal the vial. Store samples at 4 °C, and analyze within 14 days. 

CXLs also have potential as media for inorganic nanoparticle synthesis due to reasonable solubilities of material precursors, capping agents, and reducing agents,... 

Gold nanoparticles of different shapes were synthesized in the same system with and without the use of reducing agent. The surfactants act as shape regulators due to their selective adsorption to the nanoparticle surfaces resulting in different morphologies of the nanoparticles. Size control over the capped nanoparticles was obtained by altering the aqueous phase content. More relevant information can be foimd in [55-62]. 

Brust et al. have developed methods to fabricate MPC and MMPC systems that rely on the reduction of metal salts (Pd, Au, Ag, Pt) in the presence of capping ligands.5 The approach uses mild conditions and moderate reducing agents that are compatible... 

Sodium iodide 1131. Sodium iodide 1131. sodium radioiodide ( - I), lodotope. Theriodide. is. supplied in cap-. ules for oral use. or in aqueous solution for oral or parenteral uw. lodotope capsules contain I to SO mCi. and lodotope oral solutions contain 7.0S mCi/mL. Sodium iodide I 131 capsules contain 0.7 to l(K) mCi. and. sodium iodide oral alulion.s. 3.5 to ISO mCi/vial. Stock solutions ate prepared by dilution with Purified Water containing 0.2% sodium thiosulfate as a reducing agent. The dose is individualized I nr each patient. 

---